Ocrelizumab Approved in Europe (Endpoints News)

Ocrelizumab Approved in Europe (Endpoints News)
Roche's ocrelizumab (Ocrevus) has been cleared as a multiple sclerosis treatment in Europe, Endpoints News reports. Analysts expect annual sales to reach $3 billion, the type of blockbuster figure the company needs right now as key drugs like Rituxan fall prey to biosimilar competition. Ocrelizumab was approved to treat both relapsing and primary...

Roche's ocrelizumab (Ocrevus) has been cleared as a multiple sclerosis treatment in Europe, Endpoints News reports.

Analysts expect annual sales to reach $3 billion, the type of blockbuster figure the company needs right now as key drugs like Rituxan fall prey to biosimilar competition.

Ocrelizumab was approved to treat both relapsing and primary progressive MS in the U.S. in March 2017, and brought in $1 billion in sales through the end of the year.

Source: www.medpagetoday.com